The Ledger, every show

“In the first year, no formularies covered this. So it was really only for that cash payer. No insurance company picked it up, even though it was dramatically cheaper. Now it's about half of the volume, but still half not because that model of this margin sprea…”

“The idea that you're going to throw on, you know, turn a switch on a computer and it's going to think about something and event, you know, the next Prozac. I don't know. I think we're a long way from that day.”

“I don't know of one that's come through the machine driven discovery process, which is really machine plus human that's made it to the clinic yet, but they're coming.”

“The Evandia one, we know well, we work in diabetes, actually caused a policy change, and the policy change was you must rule out cardiovascular risk prior to market entry, and as you may know some conditions like diabetes have a more continuous variable you're…”

“They just analyzed our medicines, trisepatide and semaglutide, and they said, actually, they're both cost effective at current pricing. In fact, Zepbound or Trisepatide was, the threshold they have is to save a 100,000 dollars per person per year in downstream…”

“In the US, the most expensive healthcare system in the world, we spend 10 cents on the dollar on medicine. The other 90 cents go through everything else that medicine's trying to prevent.”

“Our actual net on insulin really hasn't changed. It's like 30 or 40 dollars, but the list price got up to two 75.”

“If you fund, if you went out and said, hey, I want to back some biotechs, and they sent you their business plan, 80 to a hundred percent of the revenue in return they'll pitch you on is the US. Meaning there is no return outside the US if you start at the poin…”

“We have a study reading out toward the end of this year in chronic knee pain. It's going to work.”

“So we're doing a study with our psoriasis drug, Taltz, and ZepBound. That will read out this fall. And I'm certain we'll show a boost in efficacy with the weight loss.”

“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”

“We're not used to it in the United States. Because we, one, have a, for most people, a pretty good system to subsidize some of the benefit via the insurance markets, so there's not a lot of incentive to go outside the system. That's different for these drugs, …”

“And unless some Chinese state-owned enterprise gets in this business, it'll be very hard for others to build that out and follow.”

“China's getting very good at patent hacking. So what they do is they look at that chemical structure. They work backwards, sometimes driven by AI. Algorithms define chemical structures that will behave similarly, but are outside the patent scope, and they go f…”

“So they're really quite a derivative biotech market, but that is also hurting biotech valuations in a significant way.”

“Our competitor is going to read out a study in a few months on dementia risk. It probably won't be positive. That's my guess, but it will probably be in the right direction.”

“I think we're going to get to a point. We're taking pretty low doses for most people, say over 60, 58. It's not a terrible idea. It may help you live longer.”

“The anti-fat, high-carb diets, which we were feeding people for 30 years, and I think most people don't believe in that anymore, but it led to a big part of the obesity curve, glycemic index kind of thing.”

“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”

“We just read that study out with Manjaro, which showed that three years on our drug, 94% fewer new diagnosis of outright diabetes.”

“If you're say on Medicare, currently the rule of the federal government is they won't pay. For these medications. You have to get diabetes before you can get the drug.”

“Some studies show like less than five percent of people can reach a healthy body weight on diet and exercise once they're obese.”

“Probably net pricing for us, you know, is going to be something like three, 4000 dollars a year in the steady state per person, but I think we'll create more value than that. We'll save the system more money than that per year per user.”

“Two thirds of actually our gross price goes to PBMs and insurance companies. So of the gross price that's often quoted, the net for us is about a third of that.”

“The final stage of testing, the average drug costs three and a half, four billion to make more than 60% of that is the last step.”

“Only four percent of patients who have cancer in the US are in clinical trials, whereas in Spain and Australia, it's over 25%.”

“Drug development time in the industry, It's about 10 years in the clinic, a little less right now. We're running a little less than seven at Lilly”

“And the current pricing isn't going to stay. Let's be honest. There'll be more competition. The government wants to lower our prices.”

“If you look at the large cap farmers, not Lilly, but the other ones, the multiples, the most compressed it's been in 20 years. If you look at biotech, the XBI, I think half of the XBI is trading below cash. And then if you look at. Venture. Half of the rounds …”

“Typically a generic event, you'll lose 97% of your pricing the day your patent expires.”

“Compliance is terrible. Most major hospital systems have not complied. Or if they have, they put on a website somewhere a coded database that is impossible to interpret with ICD-X codes and price points that consumers cannot digest.”

“It's 30%.”

“They had rights to the BioNTech-Pfizer vaccine for almost the entirety of their pandemic. They never approved it.”

“There are no generics manufactured in the U.S. Really.”

“There is no requirement For small molecule chemical medicine to show proof of efficacy of any kind. So you can do pretty simple laboratory experiments and absorption experiments in a small number of people.”

“Actually, the number one prescribed form of these medications is Zep-bound self-buy. We sell more than that than our insured business, a new patient starts, and more than all of we go.”

“Today we'll annualize, you know, in the billions of dollars. I think it's the largest Prescription platform online in terms of revenue. We run it on Stripe, I think, and going north from here.”

“Right now in the US, across all forms of GLP-ONE, on new patient capture, we're basically 70, 75% right now.”

“I'd estimate around twenty million take prescription GLP-I's.”

“Yeah, that's ours. Coming next year.”

“We've led in reducing the out-of-pocket costs, but from, it was originally a thousand dollars, now it's four 99 from us.”

“We currently have about 4200 PhD scientists at Lilly. By the way, it's about the same as MIT and Harvard combined.”

“Peak got to about twenty billion in new checks a year into biotech. We're now about five.”

“Half of biotech that's publicly traded is trading at or below cash.”

“So we'll get that drug in three or four years if it works, and I think it could really change some of these terrible mental health conditions.”

“Most primary care doctors are way too busy to even attend a continuing education, even know what's happening.”

“Mostly it's accurate, and they've It's gotten better over the last two years. I'd say substantially better.”

“It's hard to predict that, but I would say probably a brain disease.”